Vanda Pharmaceuticals(VNDA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results • Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023 • Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash ranges ® • Fanapt launch in bipolar I disorder; new patient starts increased by over 90% in Q3 2024 as compared to Q3 2023 • Fanapt long acting injectable program expected to be initiated in Q4 2024 ® • Milsaperidone NDA for schizophrenia and bipolar I disorde ...